Recent Updates
Recently added Catalysts
BLCO Positive Sentiment

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Tuesday, October 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bausch + Lomb Corporation announced advancements in the development of BL1243, an oral treatment for dry age-related macular degeneration (AMD). This follows a constructive meeting with the FDA, which provided clarity on the clinical development path for the investigational drug. The progress is seen as a positive step towards addressing this condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bausch + Lomb received constructive feedback from the FDA.
  • The meeting clarified the clinical development path for BL1243.
  • Progress in developing a novel treatment for dry AMD is promising.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Lead asset
brinzolamide 1%
Phase 3 · Glaucoma

Full Press Release Details

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf

Frequently Asked Questions

What is BL1243?

BL1243, also known as tonabersat, is an investigational oral treatment for dry AMD.

What did the FDA meeting clarify?

The FDA meeting provided clarity on the clinical development path for BL1243.

What condition does BL1243 aim to treat?

BL1243 aims to treat dry age-related macular degeneration (AMD).

Who is developing BL1243?

BL1243 is being developed by Bausch + Lomb Corporation.

ShareAdd on Google
Tags: BLCO Bausch + Lomb BL1243 dry AMD FDA meeting tonabersat
Last updated: Oct 6, 2026

Biotech snapshot

Cash runway
$367M liquidity · $0M/mo burn
Low dilution risk
Lead asset
brinzolamide 1%Phase 3
Glaucoma →

Catalyst track record

+13%
best trade around BLCO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for BLCO.

See every catalyst's timing & PoA →